Summary
B cell prolymphocytic leukemia (B-PLL) is a rare and aggressive disease that is associated with poor survival. Although initially asymptomatic patients do not require therapy, most patients will progress and inevitably require treatment. More than 50% of patients with B-PLL carry abnormalities in the TP53 tumor suppressor gene and/or complex karyotype and show resistance to conventional chemotherapy. The efficacy of ibrutinib, a B cell receptor inhibitor, for B-PLL with the TP53 abnormality as second-line therapy was recently demonstrated. We herein report that low-dose ibrutinib as upfront therapy induced a complete response in a B-PLL patient with the TP53 abnormality, whose condition has since remained stable with no recurrence for 12 months. Effective treatments for B-PLL are lacking and given its rarity, prospective comparative therapies are not yet available. This case suggests that upfront therapy with ibrutinib improves the outcome of B-PLL.
Similar content being viewed by others
References
Dearden C (2012) How I treat prolymphocytic leukemia. Blood 120:538–551
Ravandi F, O'brien S (2005) Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 80:1660–1674
Del Giudice I, Davis Z, Matutes E et al (2006) IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). Leukemia. 20:1231–1237
Thompson PA, O'Brien SM, Wierda WG et al (2015) Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 121:3612–3621
Sibbald R, Catovsky D (1979) Complete remission in prolymphocytic leukaemia with the combination chemotherapy---CHOP. Br J Haematol 42:488–490
Saven A, Lee T, Schlutz M, Jacobs A, Ellison D, Longmire R, Piro L (1997) Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia. J Clin Oncol 15:37–43
Hashimoto M, Suizu F, Tokuyama W et al (2013) Protooncogene TCL1b functions as an Akt kinase co-activator that exhibits oncogenic potency in vivo. Oncogenesis. 2:e70
Eyre TA, Fox CP, Shankara P, Went R, Schuh AH (2017) Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia. Br J Haematol 177:486–491
Roskoski R Jr (2016) Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms. Pharmacol Res 113:395–408
Davids MS, Brown JR (2014) Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncol 10:957–967
Gordon MJ, Raess PW, Young K, Spurgeon SEF, Danilov AV (2017) Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia. Br J Haematol 179:501–503
Damlaj M, Al Balwi M, Al Mugairi AM (2018) Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations. Leuk Lymphoma. 59:739–742
Coelho H, Badior M, Melo T (2017) Sequential kinase inhibition (Idelalisib/Ibrutinib) induces clinical remission in B-cell Prolymphocytic leukemia harboring a 17p deletion. Case Rep Hematol 2017:8563218
Tempescul A, Feuerbach J, Ianotto JC, Dalbies F, Marion V, le Bris MJ, de Braekeleer M, Berthou C (2009) A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia. Ann Hematol 88:85–88
Chow KU, Kim SZ, von Neuhoff N, Schlegelberger B, Stilgenbauer S, Wunderle L, Cordes HJ, Bergmann L (2011) Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia. Eur J Haematol 87:426–433
Weide R, Mergenthaler U, Friesenhahn V, Kleboth K, Heymanns J, Thomalla J, Köppler H (2009) Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma 50:1468–1474
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Satoko Oka declares that she has no conflict of interest. Kazuo Ono declares that he has no conflict of interest. Masaharu Nohgawa declares that he has no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from the patient.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Oka, S., Ono, K. & Nohgawa, M. Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia. Invest New Drugs 38, 1598–1600 (2020). https://doi.org/10.1007/s10637-020-00902-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-020-00902-9